The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

Condition:   Adult Attention Deficit Hyperactivity Disorder Interventions:   Drug: OPC-64005;   Drug: Atomoxetine;   Drug: Placebo Sponsor:   Otsuka Pharmaceutical Development& Commercialization, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials